GLOBAL HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MARKET 2018 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2023

Jan 2019 117

Delivery of the Report will take 2-3 working days once order is placed.

Synopsis

HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.

Scope of the Report:
This report focuses on the Hospital-Acquired Pneumonia (HAP) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.
One driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
The worldwide market for Hospital-Acquired Pneumonia (HAP) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
- Pfizer
- Merck
- Mylan
- Novartis
- Teva Pharmaceutical Industries
- AstraZeneca
- Shinogi
- Sun Pharmaceutical Industries
- The Medicines Company
- Theravance Biopharma

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- Antibacterial
- Antiviral
- Antifungal

Market Segment by Applications, can be divided into
- Hospitals
- Clinics
- Others

There are 15 Chapters to deeply display the global Hospital-Acquired Pneumonia (HAP) Drugs market.
Chapter 1, to describe Hospital-Acquired Pneumonia (HAP) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, with sales, revenue, and price of Hospital-Acquired Pneumonia (HAP) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hospital-Acquired Pneumonia (HAP) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hospital-Acquired Pneumonia (HAP) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hospital-Acquired Pneumonia (HAP) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

Related reports :

(Jan 19)

Apigenin is a polyphenol, and is one of the flavonoids found in many of the foods consumed by humans. Scope of the Report:...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for certain conditions that lead to thrombocytopenia (abn...

(Jan 19)

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for certain conditions that lead to thrombocytopenia (abn...

GLOBAL HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MARKET 2018 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2023


Share this report on:

Subscription Option


Using our subscription option, you get access to Market Research Reports and industry data of Medicine and Pharmacy market as per your needs. Get the best of Medicine and Pharmacy research reports by utilizing your research budgets in an optimum way. Contact for details

Contact for reports

*

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy